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Abstract: Type 2 Diabetes mellitus (T2D) is the most common form of diabetes and one of the most
common chronic diseases. Control of hyperglycaemia by hypoglycaemic drugs is insufficient in for
patients and nutritional approaches are currently being explored. Natural dietary compounds such as
flavonoids, abundant in fruits and vegetables, have received broad attention because of their potential
capacity to act as anti-diabetic agents. Especially cocoa flavonoids have been proved to ameliorate
important hallmarks of T2D. In this review, an update of the most relevant reports published during
the last decade in cell culture, animal models and human studies is presented. Most results support an
anti-diabetic effect of cocoa flavonoids by enhancing insulin secretion, improving insulin sensitivity
in peripheral tissues, exerting a lipid-lowering effect and preventing the oxidative and inflammatory
damages associated to the disease. While it could be suggested that daily consumption of flavanols
from cocoa or dark chocolate would constitute a potential preventive tool useful for the nutritional
management of T2D, this recommendation should be cautious since most of commercially available
soluble cocoa products or chocolates contain low amount of flavanols and are rich in sugar and
calories that may aggravate glycaemic control in T2D patients.
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1. Introduction
Type 2 Diabetes mellitus (T2D) is the most common form of diabetes and one of the most common
chronic diseases, and its prevalence is raising worldwide [1]. T2D is characterized by a sustained
hyperglycaemia due to the persistent damage in insulin secretion by pancreatic β-cell dysfunction
and by insulin resistance at the peripheral tissues [1]. However, administration of glucose-lowering
medications is insufficient to maintain glycaemic control in many patients and changes in life-style,
such as physical exercise and nutrition, both with lowest adverse side effects, are presumed to be
the most promising approaches to prevent or delay the onset of T2D. Accordingly identification of
dietary components as potential antidiabetic agents has become an essential subject in the current
research. Flavonoids, natural dietary compounds abundant in fruits and vegetables, have raised
attention because of their prospective capacity to act as anti-diabetic agents with very few adverse
side effects [1]. In particular, cocoa and its flavanols, a subfamily of flavonoids, have been proved
to ameliorate important hallmarks of T2D [1]. In this review, an update of the most relevant reports
published on this topic during the last decade in cell culture, animal models and human studies
is presented.
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2. Studies in Cultured Cells
Cultured cells constitute a useful tool to study the poorly understood anti-diabetic mechanism by
which cocoa flavanols act in vivo. By using several cultured cell lines, very appealing and encouraging
results have been reported within the last five years (Table 1).
Cocoa flavanols may improve glucose homeostasis by slowing carbohydrate digestion and
absorption in the gut. Indeed, Gu et al. [2] have shown that cocoa extracts and procyanidins
dose-dependently inhibited pancreatic α-amylase (PA), pancreatic lipase (PL), and secreted
phospholipase A2 (PLA2). These inhibitory activities were related to the polyphenolic content in
cocoa extracts and the degree of polymerization of cocoa procyanidins, showing an inverse correlation
between the inhibition and degree of polymerization (Table 1). Similarly, Yamashita et al. [3] found
that a cocoa liquor procyanidin extract (CLPr) (1–10 µg/mL) inhibited α-glucosidase activity in the
muscle L6 myotube cells. In addition, cocoa polyphenols may also inhibit certain glucose transporters.
Thus, the same CLPr increased glucose uptake in a dose-dependent manner and stimulated GLUT-4
translocation in skeletal muscle L6 cells, whereas levels of GLUT-1 and -4 remained unchanged in the
plasma membrane [3] (Table 1).
Deterioration of functional β-cell mass is observed during T2D, and this critically affects to the
maintenance of normoglycemia [1]. There are various studies that suggest that cocoa polyphenols
may protect β-cells against death-inducing damaging factors, enhance glucose stimulated insulin
secretion and induce β-cell replication. In this regard, a monomeric catechin-rich cocoa flavanol
fraction enhanced glucose-stimulated insulin secretion, while cells cultured with total cocoa extract
or with oligomeric or polymeric procyanidin-rich fractions did not show any effect demonstrated
no improvement (all substances were used at concentrations ranged 0.75–25 µg/mL) [4] (Table 1).
The increased glucose-stimulated insulin secretion in the presence of the monomeric catechin-rich
fraction was associated with enhanced mitochondrial respiration (upregulation of mitochondrial
complex III, IV and V components and increased cellular ATP production), suggesting improvements
in β-cell fuel utilization. Additionally, the monomer-rich fraction improved cellular redox state,
as increased reduced glutathione (GSH) levels and nuclear factor, erythroid 2 like 2 (Nrf2) in the nucleus
and its target genes that are essential for increasing mitochondrial function [nrf1 and GA binding
protein transcription factor alpha subunit (GABPA)] [4] (Table 1). Similarly, the main cocoa flavanol
epicatechin (EC) (100 nM) reverted mitochondrial function-associated and biogenesis-associated
indicators such as mitochondrial transcription factor A (TFAM), sirtuin (SIRT)-1, mitofilin and
peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) in high-glucose-treated
endothelial cells [5] (Table 1). Further, Martín et al. [6,7] showed that a cocoa phenolic extract (CPE)
and EC protected against oxidative stress in rat insulin-secreting INS-1 cells. Pre-treatment of cells
with EC (5–20 µM) prevented the prooxidant tert-butylhydroperoxide (t-BOOH) induced reactive
oxygen species (ROS), carbonyl groups, phosphorylated jun N-terminal kinase (p-JNK) expression and
cell death, and recovered insulin secretion [6]. Similarly, pre-treatment of cells with CPE significantly
prevented the t-BOOH-induced ROS and carbonyl groups and returned antioxidant defences [GSH
levels and glutathione peroxidase (GPx) and reductase (GR) activities] to control values [7] (Table 1).
Moreover, the microbial-derived flavonoid metabolites 3,4-dihydroxyphenylacetic acid (DHPAA,
5 µM), and 3-hydroxyphenylpropionic acid (HPPA, 1 µM) derived from flavanols metabolized by
gut microflora potentiated glucose-stimulated insulin secretion in INS-1E cells and in rat pancreatic
islets [8]. Pre-treatment of cells with both compounds protected against beta cell dysfunction and
death induced by t-BOOH through the activation of protein kinase C (PKC) and extracellular-regulated
kinases (ERK) pathways [8] (Table 1). In addition, procyanidin A2 (3–300 µM) prevented the damage
induced on insulin secretion by bisphenol A (100 µg/L) in mice isolated islets [9] (Table 1).
Cocoa flavanols may also modulate insulin signaling, which is impaired in T2D [1]. In this
line, Cordero-Herrera et al. [10,11] have reported that a CPE and EC at physiologically relevant
doses (1–10 µg/mL and 1–10 µM, respectively) enhanced the tyrosine phosphorylated and total
levels of insulin receptor (IR), insulin receptor substrate (IRS)-1, and IRS-2, and activated the
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phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway. Both natural substances also
modulated hepatic gluconeogenic and phosphoenolpyruvate carboxykinase (PEPCK) expression
through AKT and AMP-activated protein kinase (AMPK), and CPE increased GLUT-2 levels [10].
Indeed, EC and CPE alleviated the hepatic insulin resistance induced on HepG2 by treating the
cells with a high dose of glucose [11] (Table 1). Thus, EC and CPE decreased IRS-1 Ser636/639
phosphorylation, enhanced tyrosine phosphorylated and total levels of IR, IRS-1 and IRS-2 and
activated the PI3K/AKT pathway and AMPK. In addition, EC and CPE preserved HepG2 cell
functionality by restoring the levels of GLUT-2, increasing glucose uptake, maintaining glycogen
synthesis and decreasing glucose production [11]. Accordingly, EC and CPE pre-treatment prevented
high-glucose-induced ROS generation and protein carboxylation, as well as avoided the diminution
of GSH, normalized the activity of enzymatic antioxidant defences GPx, GR, catalase (CAT) and
glutathione-S-transferase (GST), and phosphorylated levels of mitogen-activated protein kinases
(p-MAPK)s, and maintained Nrf2 stimulation [12]. In this regard, the presence of selective MAPK
inhibitors induced changes in redox status, glucose uptake, p-(Ser)- and total IRS-1 levels that were
observed in CPE-mediated protection [12] (Table 1).
Early this year, cocoa procyanidin extracts have also demonstrated an insulinomimetic effect
in human primary skeletal muscle cells [13]. Indeed, a procyanidin-rich cocoa extract elicited an
antidiabetic effect by stimulating glycogen synthesis and glucose uptake, independent of insulin,
being more pronounced this effect with larger procyanidins. In this case, cocoa procyanidins
did not appear to act via stimulation of AMPK or Ca2+/calmodulin-dependent protein kinase II
activities [13] (Table 1). Similarly, previous studies suggested that cocoa also have insulinomimetic
effects in adipose tissue. Thus, a CPE (100–200 µg/mL) did not affect the levels of IR, but inhibited
the IR kinase activity by direct binding, without altering total tyrosine phosphorylation of IR or
inhibiting its auto-phosphorylation in 3T3-L1 adipocytes [14]. This inhibitory effect, which resulted
in reduced lipid accumulation and differentiation in preadipocytes in vitro, has been related to a
suppression of ERK and AKT-mediated signaling cascades to facilitate an anti-adipogenic effect;
indeed, it is thought that this is one mechanism by which cocoa flavanols may inhibit the onset of
obesity [14] (Table 1). In this regard, cocoa flavanols may improve blood glucose control indirectly,
by modulating lipid digestion and thus, reducing hyperlipidemia and its subsequent deleterious effects
on glucose homeostasis. Accordingly, Cordero-Herrera et al. [15] have reported that EC (1–10 µM)
alleviated the altered lipid values induced liver cells submitted to high glucose. The lipid-lowering
effect was related to diminished fatty acid synthesis (sterol-regulatory-element-binding protein-1-c
and fatty-acid synthase down-regulation), and increased fatty-acid oxidation [proliferator-activated
receptor (PPAR)-α up-regulation]. These effects depended on AMPK, AKT and protein kinase C ζ
(PKCζ), which phosphorylated levels returned to control values upon EC treatment, playing PKCζ a
role on AKT and AMPK regulation [15] (Table 1).
Cocoa flavanols may also contribute to prevent the chronic, low-grade, inflammation of T2D [16].
EC (0.5–10 µM) attenuated the TNFα-mediated down-regulation of peroxisome PPAR-γ expression
and decreased nuclear DNA binding in 3T3-L1 adipocytes [17]. EC also inhibited tumor necrosis
factor (TNF)α-mediated altered transcription of protein tyrosine phosphatase 1B (PTP1B), leading both
effects to an attenuation of the TNFα-mediated triggering of signaling cascades involved in insulin
resistance [17] (Table 1).
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Table 1. Anti-diabetic effects of cocoa flavanols in cultured cells a.
Effects Related to an Anti-Diabetic Action Cell Cocoa Flavanol Treatment Reference
Glucose uptake
↑ glucose uptake, ↑ GLUT-4 translocation; =GLUT-2, =GLUT-1 L6 (skeletal muscle) Cocoa liquor procyandin extract 0.05–10 µg/mL, 15 min [3]
Insulin signaling
↑ insulin secretion, ↑mitochondrial complex III-V, ↑ ATP, ↑ GSH, ↑ Nrf2, ↑ Nrf1, ↑ GABPA INS-1E (pancreas) Cocoa extract or oligomeric orpolymeric-rich fraction 0.75–25 µg/mL, 24 h [4]
↑ TFAM, ↑ SIRT-1, ↑mitofilin, ↑ PGC-1α HCAEC (endothelia) EC 100 nM, 10 min or 48 h [5]
↓ ROS, ↓ carbonyls, ↓, p-JNK, ↓ cell death, ↑ insulin secretion INS-1E (pancreas) EC 5–20 µM, 20 h [6]
↓ ROS, ↓ carbonyls, ↑ GSH, ↑ GPx, ↑ GR INS-1E (pancreas) Cocoa phenolic extract 5–20 µg/mL, 20 h [7]





5 µM DHPAA, 20 h; 1
µM HPPA, 20 h [8]
↑ Insulin secretion Mice isolated islets (pancreas) Procyanindin A2 3–300 µM, 48 h [9]
↑ p(Tyr)-IR, ↑ IR, ↑ p(Tyr)IRS-1, ↑ IRS-1, ↑ p(Tyr)IRS-2, ↑ IRS-2, ↑ p-AKT, ↑ p-GSK-3, ↑ p-AMPK,
↑ GLUT-2; ↓ p-GS, ↓ PEPCK, ↓ glucose production HepG2 Cocoa phenolic extract 1–10 µg/mL, 24 h [10]
↑ p(Tyr)-IR, ↑ IR, ↑ p(Tyr)IRS-1, ↑ IRS-1, ↑ p(Tyr)IRS-2, ↑ IRS-2, ↑ p-AKT, ↑ p-GSK-3, ↑ p-AMPK,
↓ p-GS, ↓ PEPCK, ↓ glucose production; =GLUT-2 HepG2 Epicatechin 1–10 µM, 24 h [10]
↑ p(Tyr)-IR, ↑ IR, ↑ p(Tyr)IRS-1, ↑ IRS-1, ↑ p(Tyr)IRS-2, ↑ IRS-2, ↑ p-AKT, ↑ p-GSK-3, ↑ p-AMPK,
↑ glucose uptake; ↓ p(Ser)-IRS-1; ↓ p-GS, ↓ PEPCK, ↓ glucose production; =GLUT-2,
=glycogen content
HepG2 (insulin-resistant cells) Cocoa phenolic extract 1–10 µg/mL, 24 h [11]
↑ p(Tyr)-IR, ↑ IR, ↑ p(Tyr)IRS-1, ↑ IRS-1, ↑ p(Tyr)IRS-2, ↑ IRS-2, ↑ p-AKT, ↑ p-GSK-3, ↑ p-AMPK,
↑ glucose uptake; ↓ p(Ser)-IRS-1; ↓ p-GS, ↓ PEPCK, ↓ glucose production; =GLUT-2,
=glycogen content
HepG2 (insulin-resistant cells) EC 1–10 µM, 24 h [11]
↓ ROS, ↓ carbonyls, ↑ GSH, ↑ GPx, ↑ GR, ↑ catalase, ↑ GST, ↓ p-ERK, ↓ p-JNK, ↓ p-p38, ↑ Nrf2 HepG2 (insulin-resistant cells) Cocoa phenolic extract 1–10 µg/mL, 24 h [12]
↓ ROS, ↓ carbonyls, ↑ GSH, ↑ GPx, ↑ GR, ↑ catalase, ↑ GST, ↓ p-ERK, ↓ p-JNK, ↓ p-p38, ↑ Nrf2 HepG2 (insulin-resistant cells) EC 1–10 µM, 24 h [12]
↑ glycogen synthesis, ↑ glucose uptake Human primary skeletal muscle cells Procyanidin-rich cocoa extract 10 and 25 µM, 2 h [13]
↓ p-ERK, ↓ p-AKT; =IR 3T3-L1 (adipocyte) Cocoa polyphenols 100–200 µg/mL, 4 h [14]
↓ SREBP-1c, ↓ FAS, ↑ PPAR-α, ↓ PKCζ HepG2 (insulin-resistant cells) EC 1–10 µM, 24 h [15]
↓ PPARγ, ↓ PTP1B 3T3-L1 (adipocyte) EC 0.5–10 µM, 4 h [17]
a The arrow indicates an increase (↑) or decrease (↓) in the levels or activity of the different parameters analyzed. “=” symbol indicates no changes in the parameter.
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3. Animal Studies
Animal studies offer an outstanding opportunity to assess the contribution of the physiological
effects of consumption of cocoa and cocoa components in different models of diabetes. Interestingly,
supplementation of experimental diets with cocoa has regularly shown high acceptation by the animals
and no toxicity even in chronic studies for more than 100 weeks [18]. Within the last decade different
models for experimental T2D in rats and mice have been successfully used in order to study the
nutritional prevention and treatment of the disease, and supplementation of the diet with cocoa has
proved one of the most effective nutritional approaches (Table 2).
Administration of a diet enriched with 10% cocoa for 9 weeks to Zucker diabetic fatty (ZDF) rats
reduced hyperglycaemia, enhanced insulin sensitivity and increased β-cell mass and function [19].
In particular, cocoa intake prevented β-cell apoptosis and enhanced antioxidant defences to avoid
the oxidative damage and reduce lipid and protein oxidative stress (Table 2). The same treatment
ameliorated circulating and hepatic lipid profiles [15], improved insulin resistance [20] and reverted
hepatic oxidative stress by enhancing the antioxidant capacity of hepatocytes in ZDF rats [21] (Table 2).
The lipid-lowering effect was associated to diminished fatty acid synthesis and increased fatty-acid
oxidation [15]. The decreased levels of hepatic PEPCK and increased values of GK and GLUT-2
strongly collaborate to the hypoglycaemic effect of cocoa. Moreover, increased JNK and p38 induced
by insulin resistance [20] and oxidative stress [21] was also reverted by cocoa (Table 2). Likewise,
administration of EC to obese diabetic mice for 15 weeks, prevented fat deposition and degeneration
in hepatocytes [22] (Table 2). These findings demonstrate that a diet enriched in cocoa or its main
flavanol relieves hepatic insulin resistance and oxidative stress, and improves lipid metabolism, which
are critical landmarks in the development and progression of T2D.
In the same line, feeding of ZDF rats for 7 weeks with a diet supplemented with a 5% of a soluble
cocoa product enriched in cocoa fiber decreased blood glucose and insulin and, thus, insulin resistance
measured as homeostasis model assessment of insulin resistance (HOMA-IR) index [23] (Table 2).
Likewise, administration of 8% cocoa powder for 10 to male C57BL/6J high-fat-fed obese mice resulted
in an improved HOMA-IR, indicating a reduced insulin resistance [24]. In the same study, cocoa
feeding also reduced plasma concentration of interleukin (IL)-6, monocyte chemoattractant protein-1
(MCP-1), and increased adiponectin, changes related to a reduced inflammation characteristic of
obesity and amelioration of fatty liver disease [24]. All these effects were partly mediated through
the regulation of dietary fat absorption and inhibition of macrophage infiltration in white adipose
tissue (Table 2). Likewise, decreased values of blood glucose without changes in body weight and
food consumption were observed feeding in diabetic obese mice fed with 0.5% and 1% cocoa liquor
procyanidins for 3 weeks [25] (Table 2). Furthermore, in the same mice model, administration of a
cocoa liquor procyanidin extract for 13 weeks evoked a stimulation of AMPK-α, GLUT-4 translocation
and uncoupling protein (UCP)-1 and -3 expression in skeletal muscle and adipose tissues, resulting in
a reduced obesity, hyperglycaemia, and insulin resistance [26] (Table 2). On the contrary, no changes in
glycaemia, insulinemia levels and insulin sensitivity were found in obese–diabetic rats fed a cocoa
extract enriched with polyphenol and methylxanthines [27] (Table 2).
Antioxidants 2017, 6, 84 6 of 16
Table 2. Anti-diabetic effects of cocoa and cocoa flavanols in animal studies a.
Effects Related to an Anti-Diabetic Action Animal Model Treatment Duration Reference
↓ Glucose, ↓ insulin, ↓ HOMA-IR, ↓ TG, ↓ LDL-Cho. ↑ HDL-Cho, ↓ NEFA Zucker diabetic fatty (ZDF) rats 10% cocoa powder 9 weeks [15]
↑ β-cell mass, ↑ Bcl-xL, ↓ Bax, ↓caspase-3 activity, ↑ GPx, ↑ GR, ↓ TBARS, ↓
carbonyl groups Zucker diabetic fatty (ZDF) rats (Pancreas) 10% cocoa powder 9 weeks [19]
↓ p-(Ser)-IRS-1, =IR, =IRS-1, =IRS-2, ↑ p-GSK3, ↓ p-GS, ↓ PEPCK, ↑ GK, ↑
GLUT-2, =p-ERK, ↓ p-JNK, ↓ p-p38
↓ ROS, ↓ carbonyl groups, =GSH, =GPx, =GR, =CAT, ↑ SOD, ↓ GST, ↓ HO-1, ↓
p-Nrf2, ↓ Nrf2, ↓ p65-NFkB
Zucker diabetic fatty (ZDF) rats (Liver) 10% cocoa powder 9 weeks [20,21]
↓ fat deposition, ↑ p-AMPK Obese–diabetic (db-db) mice (Liver) 0.25% EC 15 weeks [22]
↓ Glucose, ↓ insulin, ↓ HOMA-IR Obese Zucker fatty (ZF) rats 5% soluble cocoa fiber 7 weeks [23]
= Glucose, ↓ insulin ↓ HOMA-IR, ↓ IL-6
↑ adiponectin, ↓MCP-1 High-fat-fed obese C57BL/6J mice 8% cocoa powder 10 weeks [24]
↓ Glucose, ↓ fructosamine High-fat-fed obese C57BL/6J mice (Adiposetissue and skeletal muscle)
0.5% and 1% cacao liquor
proanthocyanidins 3 weeks [25]
↑ p-AMPKα, ↑ GLUT-4, ↑ UCP-1,3 High-fat-fed obese C57BL/6J mice 0.5% and 0.2% cacao liquorprocyanidin extract 13 weeks [26]
=Glucose, =insulin, =HOMA-IR Obese-diabetic (ob-db) rats 600 mg cocoa polyphenols/Kgbody weight/day 4 weeks [27]
↑ p-IR, ↑ p-IRS-1, ↑ ERK, ↑AKT, ↓ JNK, ↓ PKC, ↑ PTP1B, ↓ p-IKβ, ↓ IKK, ↓
p-p65-NFkB, ↓ TNFα, ↓MCP1, ↓ p-PERK, ↓ p-IRE1α, ↓ sXBP-1, =p-eIF2α,
=ATF6, ↓ NADPH oxidase ↓ Glucose, ↓ insulin, ↓ HOMA-IR
High-fructose (HFr)-fed rats (Liver and
adipose tissue) 20 mg EC/Kg body weight/day 8 weeks [28]
↑ p-IR, ↑ p-IRS-1, ↑ ERK, ↑AKT ↓ JNK, ↓ PKC, ↓ IKK, ↑ PTP1B High-fat-fed obese C57BL/6J mice (Liver andadipose tissue) 20 mg EC/Kg body weight/day 15 weeks [29]
↓ Glucose, ↓ insulin, ↓ ITT High-fat-fed obese C57BL/6J mice 25 mg oligomeric procyanidins/Kgbody weight/day 12 weeks [30]
a The arrow indicates an increase (↑) or decrease (↓) in the levels or activity of the different parameters analyzed. “=” symbol designates unchanged parameters.
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An EC-supplemented diet for 8 weeks alleviates insulin resistance in high-fructose-fed rats [28].
High-fructose feeding deactivated key proteins of the insulin signaling pathway resulting in a
compromised response to insulin in the liver and adipose tissue; administration of a diet supplemented
with EC partial or totally avoided these alterations. In addition, EC administration also inhibited the
activation of redox-sensitive signals, expression of pro-inflammatory cytokines and chemokines,
and endoplasmic reticulum stress proteins, effects that help to attenuate insulin resistance [28]
(Table 2). Very recently, Cremonini and colleagues [29] have reported that administration of a high-fat
diet to male C57BL/6J obese mice for 15 weeks caused obesity and insulin resistance in C57BL/6J
mice as evidenced by high fasted and fed plasma glucose and insulin levels, and impaired insulin
tolerance test (ITT) and glucose tolerance test (GTT) tests. This was associated with alterations in the
activation of components of the insulin-triggered signaling cascade in adipose and liver tissues. In this
scenario, EC supplementation ameliorated all these parameters in the high-fat fed mice, specially
improving insulin sensitivity through a downregulation of the inhibitory molecules JNK, PKC and
protein tyrosine phosphatase 1B (PTP1B) (Table 2). Finally, feeding of C57BL/6J mice submitted to
a high-fat-diet, with a cocoa flavanol extract or three flavanol fractions enriched with monomeric,
oligomeric or polymeric procyanidins for 12 weeks exerted different effects depending on the degree of
flavanol polymerization [30]. Although insulin levels were lowered by all flavanol fractions, impaired
glucose tolerance, insulin resistance, weight gain, and fat mass were most effectively avoided by the
oligomer-rich fraction [30] (Table 2).
Therefore, most studies carried out in experimental animal models endorse the favorable effect
of cocoa and its flavanols on T2D; this effect appears to be associated both to their proved beneficial
effects on vascular function and on glycaemic control through the regulation of key proteins of the
insulin signaling pathway and critical biomarkers of inflammation and stress in adipose tissue and
skeletal muscle [1].
4. Human Studies
Although most cell culture and animal studies have shown an anti-diabetic activity of cocoa and
its main flavonoids, translation of the results to humans is challenging and confirmation of cocoa
preventive efficacy against diabetes requires large and long-lasting controlled clinical trials. Within the
last few years, a significant number of systematic reviews and meta-analyses [1,31–40] point to a
positive effect of cocoa and dark chocolate on improving insulin resistance, endothelial function, blood
pressure (BP) and lipid profile. A number of prospective observations in longitudinal studies and
intervention clinical assays have yielded analogous conclusions and a few potential molecular and
biochemical mechanisms have been proposed to explain the observed benefits of cocoa and dark
chocolate for diabetics [1,33,41–43]. All this information has been pulled out from both epidemiological
and intervention studies.
Epidemiological evidence: Epidemiological evidence for an association between dietary intake of
flavanols (whatever the source) and the risk of type 2 diabetes is large and somehow inconsistent.
Three major studies could be reported as representative examples: (1) the European Prospective
Investigation into Cancer and Nutrition-InterAct (EPIC-InterAct) case-cohort study including
340,234 participants with 3.99 million person-years of follow-up in eight European countries
showed that a higher intake of flavanols was associated with a significantly reduced hazard of
diabetes [44]; (2) the Health, Alcohol and Psychosocial factors In Eastern Europe (HAPPIE) study with
5806 participants during 4 years also concluded that intake of flavanols was significantly associated
with decreased risk of T2D [45]; however, (3) in a major epidemiological study in US men and women
recruited from the Nurses’ Health Studies (NHS and NHS II) and Health Professionals Follow-Up Study
(HPFS) and during a 3,645,585 person-years of follow-up, only a higher consumption of anthocyanins
and anthocyanin-rich fruit was associated with a lower risk of T2D, whereas no association was
observed with any of the other flavonoid subfamilies [46].
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Regarding studies focusing specifically on intake of chocolate and cocoa, a recent epidemiological
study suggest that long-term intake of any type of chocolate may induce an inverse relation with
incident T2D in young and normal–body weight men [47]. In the same line, results from the
Atherosclerosis Risk in Communities (ARIC) Cohort show that the higher the frequency of chocolate
intake the lower the risk of developing diabetes; a statement valid for up to 2–6 servings (1 oz) per
week of chocolate. Consuming more than 1 serving per day did not yield significantly lower relative
risk [48]. Very recently, two large epidemiological studies have revealed contradictory data regarding
the intake of chocolate in T2D. In a prospective study longer than 30 year, a reduced incidence of
T2D was observed after a moderate chocolate intake of several times per week [49]. However, in a
long-term prospective cohort study in American postmenopausal women, Greenberg et al. concluded
that long-term consumption any type of chocolate was unable to decrease the risk of T2D [50].
Nevertheless, the beneficial effect of cocoa and chocolate in T2D has lately received unequivocal
support from meta-analysis. Hence, cocoa flavanol ingestion significantly enhanced insulin sensitivity
and ameliorated lipid profile in a recent meta-analysis of a large number of randomized controlled
trials [51]. Furthermore, the latest meta-analysis of prospective studies has concluded that a moderate
consumption of chocolate (up to 6 servings per week) is associated with a reduced risk of coronary
heart disease, stroke, and T2D [52].
Intervention studies with chocolate: Very promising results regarding chocolate intake and T2D
have been reported during the last decade (Table 3). Thus, BP was reduced and insulin sensitivity
increased in glucose-intolerant, hypertensive subjects after 15 days of consuming dark chocolate
containing 1080 mg of total polyphenols/day [53]. In this study, intake of dark chocolate enriched
with cocoa polyphenols diminished BP and HOMA-IR, augmented insulin sensitivity, and improved
β-cell function as compared to white chocolate (Table 3). In a longer intervention during 8 weeks
in diabetic patients, Mellor and colleagues [54] showed that the consumption of a high-polyphenol
chocolate containing 50 mg of EC did not evoke any change in body weight, insulin resistance, BP or
glycaemic control but significantly reduced the atherosclerotic cholesterol (Table 3). A later clinical
trial by Almoosawi and colleagues [55] demonstrated that a 4 weeks consumption of dark chocolate
containing 500 mg polyphenols by lean and overweight females evoked a significant reduction of
BP and improved blood glucose control as shown by the reduced fasting glucose and HOMA-IR
(Table 3). Furthermore, a relevant improvement in lipoprotein status and a significant decrease of
insulin resistance have been reported after administration of chocolate enriched in flavanols and
isoflavones to statin-treated diabetic women in a large study carried out in the United Kingdom (the
FLAVO study) [56,57] (Table 3). Finally and more recently, Rostami and colleagues [58] reported
that administration of chocolate enriched with cocoa polyphenols decreased fasting glucose and
ameliorated BP in patients with diabetes and hypertension (Table 3). But not all intervention studies
with chocolate have reported positive results, since fasting plasma glucose was slightly but significantly
increased in overweight men after a 4 weeks intervention with dark chocolate [59] (Table 3).
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Table 3. Anti-diabetic effects of cocoa and chocolate intake in humans a.
Effects Related to an Anti-Diabetic Action Design Population Size Duration (Days) Dose (Day) Reference
↓ HOMA-IR, ↑ QUICKI, ↑ ISI, ↑FMD, ↓BP,
↓LDL-Cho, =HDL-Cho Randomized crossover Hypertensive, glucose intolerant 38 15 1080 mg polyphenols [53]
= HOMA-IR, =BP, =LDL-Cho, ↑HDL-Cho,
=Glucose, =Insulin, =HbA1c Randomized crossover Diabetic 24 56 50 mg epicatechin [54]
↓ HOMA-IR, ↓ BP, =Insulin, ↓ Glucose Randomized crossover Overweight/obese females 42 28 500 mg polyphenols [55]
↓ HOMA-IR, =BP, ↓ LDL-Cho, =HDL-Cho,
=Glucose, ↓ Insulin, =HbA1c Randomized, placebo controlled Diabetic 93 365 850 mg flavanols [56,57]
↓ HbA1c, ↓ Glucose, =BP Randomized, placebo controlled Diabetic 60 56 450 mg flavonoids [58]
↑ Glucose Randomized crossover Overweight men 44 28 1078 mg flavanols [59]
↓ IR, ↓ BP Randomized, controlled Overweight/obese Volunteers 49 84 902 mg flavanols [60]
↑ GSH, ↑ SOD, ↑ Catalase, ↓ nitrotyrosilation and
carbonylation of proteins Open label protocol Diabetic 5 90 100 mg epicatechin [61]
↓ Glycaemia, ↓ BP, ↓MDA, ↑ HDL-Cho Randomized, controlled, crossover,free-living Moderately hypercholesterolaemic 21 60 283 mg polyphenols [62]
↓ Glycaemia, ↓ IL-1b, IL-10, =VCAM1 Randomized, controlled, crossover,free-living Moderately hypercholesterolaemic 44 28 416 mg flavanols [63]
↓ Glycaemia, ↓ IL-1b, ↑ HDL-Cho Randomized, controlled, crossover,free-living Moderately hypercholesterolaemic 44 28 43.8 mg flavanols [64]
↓ LDL-Cho, ↓ HDL-Cho, ↓ inflammatory markers Randomized Diabetic 100 42 10 g cocoa powder [65]
↑ HDL-Cho, ↑ Ins, =LDL Cho, =TG, =Glucose,
=IR, =BP Randomized, crossover trial Diabetic 18 Acute, 6 h
960 mg polyphenols
(480 flavanols) [66]
=BP, =glycaemic parameters Randomized, placebo-controlled,double-blind, crossover trial Hypertensive 20 14
Cocoa beverage
(900 mg flavanols/day) [67]
=glycaemic parameters, =BP Randomized, double-masked fashion Diabetic 41 30 Flavanol-rich cocoa(963 mg flavanols/day) [68]
=Glycaemic parameters, =IL-6, =CRP Randomized crossover design Obese adults 20 5 Cocoa beverage(900 mg flavanols/day) [69]
↓ IR (HOMA-IR), =Glucose, =BP Randomized, double-blind,placebo-controlled, crossover trial Healthy 37 28 100 mg epicatechin [70]
a The arrow indicates an increase (↑) or decrease (↓) in the levels or activity of the different parameters analyzed. “=” symbol designates unchanged parameters.
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Intervention studies with cocoa and pure flavanols: Cocoa supplementation of the diet has proved
both effective and innocuous for glycaemic control in humans (Table 3). Thus, consumption of a
cocoa diet enriched with flavanols (902 mg flavanols/day) for 12 weeks by overweight and obese
adults considerably improved endothelial function, decreased insulin resistance and reduced diastolic
and mean arterial BP as compared to those that received a low-flavanol cocoa diet [60] (Table 3).
Treatment for three months with cocoa rich in EC evoked a positive regulation of oxidative stress
biomarkers in skeletal muscle of patients with heart failure and T2D [61] (Table 3). A slight but
significant hypoglycaemic effect has been reported in moderately hypercholesterolemic humans
after administration for 2 months of a fiber-rich cocoa product providing a daily dose of 12 g of
dietary fiber and 283 mg of soluble polyphenols [62] or after administration for 4 weeks of a cocoa
product providing a daily dose of 416 mg of flavanols [63] (Table 3). In agreement with these results,
administration for 4 weeks of a commercialized soluble cocoa product rich in dietary fiber providing
43.8 mg flavanols daily to healthy and moderately hypercholesterolemic subjects induced a slight
decrease of postprandial blood glucose [64] (Table 3). In patients with T2D, cocoa powder intake for six
weeks reduced total blood cholesterol, LDL-cholesterol and biomarkers of inflammation [65], and, in an
acute assay, cocoa supplementation of a high-fat breakfast raised postprandial serum HDL-cholesterol
and insulin [66] (Table 3). However, some studies failed to show an effect of a cocoa diet on T2D
biomarkers. In a study by Muniyappa and co-workers [67], an improved endothelial function without
changes in BP or insulin sensitivity was reported after ingestion of a cocoa drink rich in flavanols
(nearly 900 mg of flavanols in 150 mL twice a day) for 2 weeks in patients with hypertension (Table 3).
Moreover, in a study by Balzer and colleagues [68], a substantial increase in fasting flow-mediated
vascular dilation along with no changes in glycaemic control, BP and heart rate were observed in T2D
patients that received a diet supplemented with cocoa with a high daily dose of 963 mg of flavanols
for 30 days (Table 3). Furthermore, a short-term intake of a cocoa beverage rich in flavanols by obese
adults at risk for insulin resistance reduced critical markers of oxidative stress and inflammation but
did not improve glucose metabolism [69] (Table 3).
Regarding administration of pure flavanols, EC supplementation to healthy adults decreased
fasting blood insulin and insulin resistance (HOMA-IR) but had no effect on fasting blood glucose, BP
and arterial stiffness, nitric oxide and endothelin 1 concentration, or blood lipid profile [70] (Table 3).
Overall, most of the above studies support the notion that regular intake of foods rich in cocoa or
cocoa flavanols could endorse a dietary strategy to appease insulin resistance. Accordingly, EC has
been very recently suggested as adjuvant of metformin in the therapy for T2D patients [71].
Cocoa and body weight: A very exciting outcome in recent human intervention studies with cocoa is
that cocoa supplementation of diets did not evoke any increase in body weight or other anthropometric
changes [72–74]. Thus, administration of diets supplemented with up to 12.5% of cocoa powder
has unequivocally shown anti-obesity effects in rats [19–21,24,75–77]. In addition, despite the fact
that cocoa products commercially available are frequently high-caloric foodstuffs, they have been
reported to have a similar effect in humans [72–74,78]. However, this anti-obesity effect of cocoa and
its derivatives in humans has lately been challenged; i.e., in a prospective cohort study, Greenberg
and co-workers [79] have reported a dose-response greater prospective weight gain over time after
a regular chocolate consumption. In fact, the highest weight gain was reported in volunteers with
the largest frequency of chocolate ingestion, which could be partially related to diminished satiety
prompted by the habitual intake of chocolate. It is worth remarking that no differences among different
types of chocolate (white, milk and plain) were considered in the previous work [79]. Another study
by the same group in the Women’s Health Initiative cohort, reported that a greater ingestion of
chocolate-candy, usually milk chocolate, was associated to a higher weight gain during a 3-year study
period with postmenopausal women [80]. It ought to be stated that habitual consumption of dark
chocolate, rather than milk chocolate, will prompt long-term cardiovascular benefits with a minor risk
of weight gain [76]. In addition, a stronger sense of satiety and reduced need for energy intake can be
more easily achieved after consumption of dark chocolate rather than milk chocolate [81], but a recent
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study by Esser and colleagues [59] has shown that increased flavanol content in chocolate does affect
taste and has a negative effect on the motivation to eat chocolate.
In summary, most of the data above suggest that the beneficial effect of cocoa and its flavanols
on T2D seems to be associated to their substantiated favorable effects on vascular function and on
glycaemic control mediated through the regulation of main proteins involved in the insulin signalling
pathway, as well as in the processes of inflammation and oxidative stress. The precise biochemical
and molecular mechanisms have recently been reviewed [1,43]. Additionally, the European Food
Safety Authority (EFSA) sanctions that cocoa flavanols help maintain normal blood pressure [82] and
endothelium-dependent vasodilation [83], and, in the context of a healthy diet, the claimed effect can
be obtained with a daily consumption of 200 mg of cocoa flavanols. This amount of flavanols can be
acquired with the intake of 100 g of most cocoa soluble products or 40 g of any >70% cocoa chocolate
in the market.
Finally, some gaps in the research to delineate the anti-diabetic effect of a cocoa intake have
been detected in the literature; thus, the role of three compounds should be promptly investigated,
should be investigated: (i) host and microbiota-derived flavanol metabolites; (ii) cocoa fiber and (iii)
theobromine. All three have shown promising beneficial effects on cardiovascular health and body
weight control and they should be considered in future controlled clinical trials.
5. Conclusions
Most studies within the last decade support a substantial role for cocoa and its flavanols in the
nutritional prevention of T2D. Cocoa flavanols act by (a) regulating carbohydrate absorption in the
gut; (b) protecting β-pancreatic cells function and enhancing insulin secretion; (c) improving insulin
sensitivity in peripheral tissues such as liver, adipose tissue and skeletal muscle through regulation of
glucose transporters and main proteins of the insulin signalling pathway; (d) exerting a lipid-lowering
effect and; (e) preventing the exacerbated oxidative stress and inflammation characteristics of the
disease. All these effects contribute to improve the insulin sensitivity and to maintain normoglycaemia,
and thus, to avert and/or significantly delay the onset of T2D and development of its complications.
Consequently, a moderate daily consumption of flavanols from cocoa or dark chocolate, along with an
everyday intake of other dietary flavonoids, could be a valuable recommendation for the nutritional
management of this disease. However, it is worth remembering that most of commercially available
soluble cocoa products or chocolates contain low amount of flavanols and are rich in sugar and calories
that may aggravate glycaemic control in T2D patients. Hence, recommendation of consumption
of chocolate or other cocoa derivatives to this population still requires further research, especially
extensive well-designed human epidemiological and intervention studies, to delineate the amount
of cocoa and variety of its products that might be beneficial to prevent, delay or contribute to the
treatment of T2D.
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